Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

Clasp Therapeutics announced dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumor-specific T cell engagers to enter clinical development.